Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

PR Newswire September 27, 2023

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

GlobeNewswire September 11, 2023

Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

GlobeNewswire September 7, 2023

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

GlobeNewswire August 28, 2023

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

GlobeNewswire August 11, 2023

Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

GlobeNewswire August 8, 2023

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

GlobeNewswire July 26, 2023

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 10, 2023

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

GlobeNewswire June 27, 2023

Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

GlobeNewswire June 21, 2023

Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023

GlobeNewswire June 12, 2023

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 24, 2023

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

GlobeNewswire May 15, 2023

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator

GlobeNewswire May 2, 2023

Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

GlobeNewswire April 25, 2023

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

GlobeNewswire April 21, 2023

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

GlobeNewswire March 30, 2023

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

GlobeNewswire March 23, 2023

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

GlobeNewswire February 16, 2023

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

GlobeNewswire February 13, 2023